The course of peripheral neuropathy and its association with health-related quality of life among colorectal cancer patients
Bonhof, C.S.; van de Poll-Franse, L.V.; Wasowicz, D.K.; Beerepoot, L.V.; Vreugdenhil, G.; Mols, F.

Published in:
Journal of Cancer Survivorship

DOI:
10.1007/s11764-020-00923-6

Publication date:
2021

Document Version
Publisher's PDF, also known as Version of record

Link to publication in Tilburg University Research Portal

Citation for published version (APA):
Bonhof, C. S., van de Poll-Franse, L. V., Wasowicz, D. K., Beerepoot, L. V., Vreugdenhil, G., & Mols, F. (2021). The course of peripheral neuropathy and its association with health-related quality of life among colorectal cancer patients. Journal of Cancer Survivorship, 15(2), 190-200. https://doi.org/10.1007/s11764-020-00923-6

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 16. jul. 2021
The course of peripheral neuropathy and its association with health-related quality of life among colorectal cancer patients

Cynthia S. Bonhof 1,2 • Lonneke V. van de Poll-Franse 1,2,3 • Dareczka K. Wasowicz 4 • Laurens V. Beerepoot 5 • Gerard Vreugdenhil 6 • Floortje Mols 1,2

Received: 26 May 2020 / Accepted: 31 July 2020 / Published online: 13 November 2020
© The Author(s) 2020

Abstract

Purpose To gain more insight into the course of chemotherapy-induced peripheral neuropathy (CIPN) and its impact on health-related quality of life (HRQoL) in a population-based sample of colorectal cancer (CRC) patients up to 2 years after diagnosis.

Methods All newly diagnosed CRC patients from four hospitals in the Netherlands were eligible for participation in an ongoing prospective cohort study. Patients (n = 340) completed questions on CIPN (EORTC QLQ-CIPN20) and HRQoL (EORTC QLQ-C30) before initial treatment (baseline) and 1 and 2 years after diagnosis.

Results Among chemotherapy-treated patients (n = 105), a high sensory peripheral neuropathy (SPN) level was reported by 57% of patients at 1 year, and 47% at 2-year follow-up, whereas a high motor peripheral neuropathy (MPN) level was reported by 47% and 28%, at years 1 and 2, respectively. Linear mixed model analyses showed that SPN and MPN symptoms significantly increased from baseline to 1-year follow-up and did not return to baseline level after 2 years. Patients with a high SPN or MPN level reported a worse global quality of life and a worse physical, role, emotional, cognitive, and social functioning compared with those with a low SPN or MPN level.

Conclusions Future studies should focus on understanding the mechanisms underlying CIPN so targeted interventions can be developed to reduce the impact of CIPN on patient’s lives.

Implications for cancer survivors Patients need to be informed of both CIPN and the impact on HRQoL.

Keywords Peripheral neuropathy • Colorectal cancer • Health-related quality of life • PROFILES

Abbreviations

PROFILES Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship

PROs Patient-reported outcomes
NCR Netherlands Cancer Registry
HRQoL Health-related quality of life
CIPN Chemotherapy-induced peripheral neuropathy

PN Peripheral neuropathy
SPN Sensory peripheral neuropathy
MPN Motor peripheral neuropathy
MPN Autonomic peripheral neuropathy
CRC Colorectal cancer

Colorectal cancer (CRC) is the third most common cancer among men and women [1]. In 2019, 12,900 patients were diagnosed in the Netherlands. Fortunately, survival rates have improved remarkably as a result of earlier detection and

1 Department of Medical and Clinical Psychology, CoRPS - Center of Research on Psychology in Somatic disorders, Tilburg University, Tilburg, The Netherlands
2 Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands
3 Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
4 Department of Surgery, Elisabeth-TweeSteden hospital, Tilburg, the Netherlands
5 Department of Internal Medicine, Elisabeth-TweeSteden hospital, Tilburg, the Netherlands
6 Department of Internal Medicine, Máxima Medical Centre, Eindhoven and Veldhoven, The Netherlands

https://doi.org/10.1007/s11764-020-00923-6
Journal of Cancer Survivorship (2021) 15:190–200
improved treatment strategies. In the past 20 years, the 5-year survival rate has increased from 54 to 66% in the Netherlands [2]. The increasing number of CRC survivors highlights the need to focus on the side effects of cancer and its treatment.

A common and severe side effect is chemotherapy-induced peripheral neuropathy (CIPN), which is the result of damage to the peripheral nerves caused by chemotherapy. The prevalence differs depending on type of chemotherapeutic agent and method of assessment. However, a meta-analysis reported an overall prevalence of 68% in the first month after chemotherapy, and 30% at 6 months or more [3]. There is currently no strategy available to prevent CIPN and pharmacological options to manage established CIPN are limited [4]. Therefore, the development of severe CIPN is often a reason for dose reduction or even discontinuation of the chemotherapeutic agent, compromising the efficacy of treatment and patient survival [5].

CIPN symptoms in CRC are primarily sensory (e.g., tingling, numbness, and pain in the extremities), but can be motoric (e.g., cramps and loss of strength), or autonomic (e.g., dizziness after standing up and blurry vision) as well [5]. These symptoms can cause problems with regular daily activities, which are likely to compromise health-related quality of life (HRQoL). This was indeed the conclusion of a review on CIPN and HRQoL [6]. Among patients with CRC, several studies examined the relationship between CIPN and HRQoL [6–10]. We previously showed in an analyses of 1643 CRC survivors 2–11 years after diagnosis that neuropathy was negatively related with all scales of the EORTC QLQ-C30 questionnaire [7]. However, most studies, including ours have been cross-sectional. In addition, while several studies among CRC patients have examined the course of CIPN over time, most studies did either not include a CIPN measurement before the start of chemotherapy, did not examine the course longer than 1 year after diagnosis, or did not distinguish between sensory (SPN), motor (MPN), and autonomic (APN) peripheral neuropathy (PN) [11–13].

Gaining more insight into the course of CIPN and its influence on HRQoL is important to be able to inform and guide CRC patients and clinicians in their decision-making regarding treatment. Therefore, our aim is to prospectively examine (1) the prevalence and course of SPN, MPN, and APN and (2) their association with HRQoL among a population-based sample of CRC patients from diagnosis up to 2 years after diagnosis.

**Methods**

**Setting and participants**

The PROCORE study is an ongoing prospective, population-based study among CRC patients, aimed to examine the impact of CRC and its treatment on patient-reported outcomes. Data collection was performed within PROFILES (Patient Reported Outcomes Following Initial Treatment and Long Term Evaluation of Survivorship), a registry for the physical and psychological impact on cancer and its treatment [14]. PROFILES is directly linked to the Netherlands Cancer Registry (NCR) that collects data from all newly diagnosed cancer patients [2]. Patients were recruited from four Dutch hospitals: Elisabeth-TweeSteden hospital, Catharina hospital, Elkerliek hospital, and Máxima Medical Centre.

All patients newly diagnosed with CRC as a primary tumor between January 2016 and January 2019 were invited to participate. Exclusion criteria were the following: previous cancer diagnosis (except for basal cell carcinoma), cognitive limitations, and the inability to read or write Dutch. All eligible patients were included shortly after diagnosis, before the start of initial treatment. However, some patients who were previously diagnosed with cancer and those who already started treatment were also included. Therefore, patients were excluded for analysis if (1) they were previously diagnosed with cancer and reported baseline EORTC QLQ-CIPN20 scores > 0, or (2) they already started chemotherapy.

**Data collection**

From their research nurse or case manager, patients received an information package, containing an information letter, informed consent form, and the first questionnaire. In the first questionnaire, patients could indicate if they wanted to receive the follow-up questionnaires online. After patients had provided their consent, follow-up questionnaires were sent 4 weeks after surgery (when applicable), and 1 and 2 years after diagnosis. As the questionnaire 4 weeks after surgery did not contain questions on CIPN, it was not included in the analysis. The PROCORE study was approved by the Medical research Ethics Committees United (approval number NL51119.060.14).

**Sociodemographic and clinical characteristics**

Patients’ sociodemographic (i.e., age, sex) and clinical information (e.g., cancer type, clinical stage, surgery (yes/no), chemotherapy (yes/no), and radiotherapy (yes/no)) was obtained from patients’ medical records by the NCR [2]. Educational level and partner status were assessed in the questionnaire. Comorbidity was assessed with the adapted Self-administered Comorbidity Questionnaire [15].

**PN**

PN symptoms were assessed with the EORTC QLQ-CIPN20 [16], which contains three subscales, assessing SPN, MPN, and APN symptoms. Items are measured on a Likert scale,
ranging from (1) not at all to (4) very much. Scores are transformed to a 0–100 scale, with higher scores representing more complaints [17].

Because PN symptoms can also be present in people without cancer, which are then associated with comorbidity and normal aging [18], we wanted to distinguish patients with a high PN level from those with symptoms in the normal range. Therefore, Dutch age and sex-specific normative EORTC QLQ-CIPN20 data [18] and the minimal clinically important difference (MCID) of the CIPN20 (i.e., 2.5 for SPN and 2.6 for MPN) were used [19]. For example, in the general population, men aged 60–69 years reported a mean SPN score of 2.9. Therefore, in the current study, men in this age group were categorized into “high SPN” if they had a sensory score of ≥ 5.4 (2.9 + 2.5), and into “low SPN” if they reported scores < 5.4. No categorization was done for APN, as no MCID is available [19].

### Health-related quality of life

The EORTC QLQ-C30 was used to assess HRQoL [20]. In this study, only the global health status/QoL scale and the five functioning scales were used. Items are scored on a Likert scale from (1) not at all to (4) very much, except for the global QoL scale, which ranges from (1) very poor to (7) excellent. Scores were linearly transformed to a 0–100 scale, with higher scores representing better QoL/functioning [17].

### Statistical analyses

NCR data on sociodemographic and clinical characteristics enabled us to compare eligible patients and respondents, and those who completed baseline and either 1-year follow-up or 2-year follow-up with patients who completed all questionnaires, using t tests for continuous variables and chi-square (or Fisher’s exact) tests for categorical variables. All other analyses are based on patients who completed at least two questionnaires. First, differences in patient characteristics between patients who received chemotherapy and those who did not were assessed with t tests for continuous variables and chi-square tests for categorical variables.

Then, logistic regression analyses were performed to detect differences in PN symptoms at 1-year and 2-year follow-up between patients who were given chemotherapy and those who were not. For these analyses, the individual items of the EORTC QLQ-CIPN20 were used and the answer categories “quite a bit” and “very much” were combined. Analyses were adjusted for age, diabetes mellitus, osteoarthritis, and rheumatoid arthritis, which are variables known or expected to impact PN.

The SPN, MPN, and APN courses were examined using linear mixed models (LMM), with maximum likelihood estimation and an unstructured covariance matrix with a 2-level structure (i.e., repeated time points [lower level], patients [higher level]). Time was analyzed as a regular categorical predictor with three levels (i.e., three time points). These analyses were adjusted for age, diabetes mellitus, osteoarthritis, and rheumatoid arthritis. Differences in SPN, MPN, and APN between patients with or without chemotherapy were examined similarly, but without time as a predictor. Unstandardized regression coefficients (E) are reported. Clinically important differences were determined using the MCID [19].

To detect differences in HRQoL between patients according to the stability of their SPN or MPN levels, t tests were conducted. For this, patients were categorized into “ever SPN” if they reported high SPN on at least one of the three time points; otherwise, they were categorized into “never SPN.” The same was done for MPN. Clinically important differences were determined using EORTC QLQ-C30 guidelines [21].

Finally, the impact of SPN and MPN on HRQoL over time was examined with LMM. SPN and MPN were included as dichotomous variables (high vs. low level of SPN/MPN) and analyzed as time-varying predictors, while for the confounding background variables age, sex, partner status, education level, tumor type, stage, osteoarthritis, rheumatoid arthritis, and diabetes mellitus baseline characteristics were used.

Analyses were performed using SPSS 22 (IBM SPSS Statistics for Windows, version 22.0 Armonk, NY: IBM Corps USA). p values < 0.05 were considered statistically significant.

### Results

#### Patient characteristics

Of the 713 CRC patients who were invited to the study, 66.9% (n = 477) completed the questionnaire at baseline, 50.4% (n = 359) at 1-year follow-up, and 28.5% (n = 203) at 2-year follow-up (Fig. 1.). As the study is still ongoing, not all patients have yet received the questionnaire at 1-year and 2-year follow-up. Compared with all patients eligible for participation, respondents were younger (70 vs. 67 years, p < 0.001), more often male (56% vs. 61%, p = 0.04), they received chemotherapy more often (26% vs. 31%, p = 0.02), and surgery less often (100% vs. 98%, p < 0.001). Furthermore, they were less often diagnosed with rectosigmoid cancer (5% vs. 3%, p = 0.02), they more often had stage III cancer (29% vs. 37%, p = 0.003), and an unknown stage (1% vs. 2%, p < 0.001), and less often stage IV cancer (11% vs. 4%, p < 0.001). No differences in sociodemographic and clinical characteristics were found between patients who completed at least two questionnaires and patients who completed all three questionnaires (data not shown).

Further analyses were done among respondents who completed at least two questionnaires (n = 340). Among these patients, chemotherapy-treated patients (n = 105, 31%) were...
younger, they less often had at least 2 comorbidities, and they more often had a higher disease stage compared with those not treated with chemotherapy (n = 235, 69%) (Table 1). They were also more often treated with radiotherapy, but less often
received surgery. No data on chemotherapy regimen (e.g., type of chemotherapy administered, number of chemotherapy cycles, and dosage) was available.

**Peripheral neuropathy**

At 1-year follow-up, chemotherapy-treated patients reported tingling fingers or hands, tingling toes or feet, numbness in fingers or hands, numbness in toes or feet, and trouble handling small objects significantly more often compared with those not treated with chemotherapy (Table 2). At 2-year follow-up, they still more often reported tingling toes or feet and numbness in toes or feet.

The prevalence of a high SPN and MPN level (using MCID + normscores) was also examined. While for SPN, no differences between chemotherapy-treated patients and those without chemotherapy were found at baseline (11% vs. 16%; \( p = 0.17 \)); chemotherapy-treated patients did more often report a high SPN level at 1-year (57% vs. 24%; \( p < 0.001 \)) and 2-year follow-up (47% vs. 31%; \( p = 0.03 \)).
Regarding MPN, chemotherapy-treated patients reported a high MPN level more often compared with those not treated with chemotherapy, but only at 1-year follow-up (47% vs. 32%; \(p = 0.02\)). No differences were found at baseline (15% vs. 23%; \(p = 0.13\)) and 2-year follow-up (28% vs. 35%; \(p = 0.34\)).

### Course of peripheral neuropathy

For chemotherapy-treated patients, SPN increased significantly at 1-year follow-up. Furthermore, while the SPN mean score then did significantly decrease at 2-year follow-up, it remained significantly higher compared with baseline. All changes in mean score were significant (all three \(p < 0.001\)) and clinically relevant (Fig. 2). For patients not treated with chemotherapy, SPN increased at 1-year (\(p = 0.001\), not clinically relevant) and at 2-year follow-up remained stable, but still significantly higher compared with baseline (\(p < 0.001\), clinically relevant). Finally, chemotherapy-treated patients reported a higher SPN mean score at 1-year (\(p < 0.001\)) and 2-year follow-up (\(p = 0.001\)). These differences were clinically relevant.

For MPN, the mean score increased for both chemotherapy-treated patients and those not treated with chemotherapy at 1-year (both \(p < 0.001\)), and at 2-year follow-up remained stable and still significantly higher compared with baseline (\(p = 0.004\) and \(p < 0.001\)). However, the significant differences were only clinically relevant for chemotherapy-treated patients. Moreover, chemotherapy-treated patients reported a higher MPN mean score, but only at 1-year follow-up (\(p = 0.007\), clinically relevant).

Finally, APN showed a stable course among chemotherapy-treated patients, while for those not treated with chemotherapy, there was a small increase at 1-year follow-up (\(p = 0.048\), not clinically relevant). No differences were found between chemotherapy-treated patients and those not treated with chemotherapy.

### Table 2  Peripheral neuropathy symptoms among colorectal cancer patients at 1-year and 2-year follow-up, stratified by chemotherapy

|                  | Year 1            | Year 2            |
|------------------|-------------------|-------------------|
|                  | CT \((n = 99)\)   | No CT \((n = 226)\) | \(p\)   | CT \((n = 59)\) | No CT \((n = 131)\) | \(p\)   |
| **Sensory symptoms and problems** |                   |                   |         |                   |                   |         |
| 1. Tingling fingers or hands | 25 (25%) | 13 (6%) | \(< 0.001\) | 7 (12%) | 7 (5%) | 0.28 |
| 2. Tingling toes or feet | 36 (36%) | 10 (4%) | \(< 0.001\) | 10 (17%) | 5 (4%) | 0.008 |
| 3. Numbness in fingers or hands | 15 (15%) | 2 (1%) | \(< 0.001\) | 3 (5%) | 2 (2%) | 0.28 |
| 4. Numbness in toes or feet | 20 (20%) | 5 (2%) | \(< 0.001\) | 7 (12%) | 4 (3%) | 0.02 |
| 5. Shooting or burning pain in fingers or hands | 6 (6%) | 4 (2%) | 0.16 | 2 (3%) | 2 (2%) | 0.31 |
| 6. Shooting or burning pain in toes or feet | 8 (8%) | 7 (3%) | 0.07 | 5 (9%) | 6 (5%) | 0.20 |
| 9. Trouble standing or walking | 10 (10%) | 4 (2%) | \(0.002\) | 4 (7%) | 4 (3%) | 0.99 |
| 10. Trouble distinguishing temperature of hot and cold water | 2 (2%) | 2 (1%) | 0.53 | 2 (3%) | 0 (0%) | 0.99 |
| 18. Trouble hearing | 9 (9%) | 20 (9%) | 0.50 | 6 (10%) | 11 (8%) | 0.42 |
| **Motor symptoms and problems** |                   |                   |         |                   |                   |         |
| 7. Cramps in hands | 4 (4%) | 7 (3%) | 0.79 | 2 (3%) | 7 (5%) | 0.67 |
| 8. Cramps in feet | 4 (4%) | 7 (3%) | 0.76 | 4 (7%) | 6 (5%) | 0.47 |
| 11. Trouble holding a pen which made writing difficult | 1 (1%) | 4 (2%) | 0.50 | 1 (2%) | 2 (2%) | 0.93 |
| 12. Trouble handling small objects (e.g., buttoning a blouse) | 15 (15%) | 9 (4%) | \(< 0.001\) | 5 (9%) | 6 (5%) | 0.10 |
| 13. Trouble opening jar/bottle due to loss of strength in hands | 12 (12%) | 17 (8%) | 0.28 | 3 (5%) | 11 (9%) | 0.59 |
| 14. Trouble walking because your feet come down to hard | 3 (3%) | 1 (0.4%) | 0.08 | 2 (3%) | 1 (1%) | 0.27 |
| 15. Trouble walking stairs or standing up from a chair due to weakness in legs | 8 (8%) | 11 (5%) | 0.28 | 3 (5%) | 4 (3%) | 0.54 |
| 19. Only for those driving cars: Trouble driving due to use of pedals | 2 (2%) | 2 (1%) | 0.60 | 2 (4%) | 0 (0%) | 0.99 |
| **Autonomic symptoms and problems** |                   |                   |         |                   |                   |         |
| 16. Dizziness after standing up | 5 (5%) | 9 (4%) | 0.60 | 1 (2%) | 5 (4%) | 0.53 |
| 17. Blurry vision | 2 (2%) | 8 (4%) | 0.83 | 1 (2%) | 4 (3%) | 0.69 |
| 20. Only for men: Trouble getting or maintaining an erection | 20 (30%) | 40 (35%) | 0.79 | 12 (32%) | 33 (47%) | 0.21 |

Italicized \(p\) values indicate statistically significance. The number of patients reported in this table reflects the patients who answered “quite a bit” or “very much” on the EORTC QLQ-CIPN20 items.

Analyses were adjusted for age, diabetes mellitus, osteoarthritis, and rheumatoid arthritis.
Fig. 2 Course of sensory, motor, and autonomic peripheral neuropathy among colorectal cancer patients, stratified by chemotherapy. A higher score on the scales indicates more neuropathy symptoms. The scale in this figure ranges from 0 to 50 for clear visibility of the course of the peripheral neuropathy symptoms, while total scores of the EORTC QLQ-CIPN20 range from 0 to 100.
Fig. 3 Course of health-related quality of life for colorectal cancer patients according to them ever or never reporting high sensory peripheral neuropathy (a) or motor peripheral neuropathy (b). *Significant difference between patients who “ever” reported high SPN/MPN and those who “never” reported high SPN/MPN, but of no clinical relevance. ‡Significant difference, of medium clinical relevance. †Significant difference, of large clinical relevance. The scale in this figure ranges from 50 to 100 for clear visibility of the association between peripheral neuropathy and health-related quality of life, while total scores of the EORTC QLQ-C30 range from 0 to 100

Peripheral neuropathy and HRQoL

In further analyses, both patients who received chemotherapy and those who did not were included in the analyses. At baseline, patients in the “ever high SPN” group reported worse global quality of life, and worse physical, emotional, cognitive, and social functioning compared with patients who never reported high SPN (Fig. 3). However, only the difference in global quality of life and cognitive functioning were of (small) clinical relevance. At 1-year and 2-year follow-up, patients in the “ever high SPN” group reported worse scores on all six HRQoL scales, which were of small to medium clinical relevance.

For MPN, patients in the “ever high MPN” reported worse scores on all six HRQoL scales at all three time points (Fig. 3). However, at baseline, only the differences in global quality of life and physical, cognitive, and social functioning were of (small) clinical relevance. At 1- and 2-year follow-up, all differences were clinically relevant (small to medium).

Between-patients and within-patients effects of peripheral neuropathy on HRQoL

CRC patients with a high SPN level reported a worse global quality of life \( (E = -11.87, p < 0.001) \) and a worse physical \( (E = -11.34, p < 0.001) \), role \( (E = -11.46, p < 0.001) \), emotional \( (E = -9.59, p < 0.001) \), cognitive \( (E = -13.43, p < 0.001) \), and social functioning \( (E = -10.62, p < 0.001) \) compared with those with a low SPN level (between-patients effects). Furthermore, patients who changed from a low to a high SPN level over time showed a decrease in physical \( (E = -8.24, p < 0.001) \), role \( (E = -8.83, p < 0.001) \), cognitive \( (E = -6.47, p < 0.001) \), and social \( (E = -5.72, p = 0.001) \) functioning, while patients who changed from a high to a low SPN level over time showed improvements in these areas (within-patients effects).

For MPN, those with a high MPN level also reported a worse global quality of life \( (E = -11.86, p < 0.001) \) and a worse physical \( (E = -14.16, p < 0.001) \), role \( (E = -13.35, p < 0.001) \), emotional \( (E = -8.36, p < 0.001) \), cognitive \( (E = -12.81, p < 0.001) \), and social \( (E = -11.10, p < 0.001) \) functioning compared with those with a low MPN level. In addition, patients who changed from a low to a high MPN level over time showed a decrease in global quality of life \( (E = -6.62, p < 0.001) \) and physical \( (E = -10.59, p < 0.001) \), role \( (E = -14.91, p < 0.001) \), cognitive \( (E = -5.41, p < 0.001) \), and social \( (E = -7.59, p < 0.001) \) functioning, while those who changed from a high to a low MPN level over time showed improvements on these scales.

Discussion

In this longitudinal study among CRC patients, we first showed that, at 1-year follow-up, chemotherapy-treated patients more often reported tingling fingers or hands, tingling toes or feet, numbness in fingers or hands, numbness in toes or feet, and trouble handling small objects, compared with those not treated with chemotherapy. At 2-year follow-up, they still more often reported tingling and numbness in toes or feet. These results are in line with prior research, in which it was also found that symptoms in the hands are more prominent during and shortly after chemotherapy, while symptoms in the feet are more prominent months after chemotherapy [7, 22, 23]. Also, the overall CIPN prevalence is reported to be 30% at 6 months or more after chemotherapy [3]. While in this study the prevalence rate of MPN at 2-year follow-up (28%) supports those findings, the reported SPN (47%) is much higher.

Looking at the course of PN, both SPN and MPN were impacted by chemotherapy, and the reported SPN and MPN did not return to baseline level after 2 years. However, at 2-year follow-up, the MPN level did decline to the same level as those not treated with chemotherapy. The finding that SPN was mostly impacted by chemotherapy is supported by previous studies [7, 11, 13]. The question remains whether SPN symptoms will continue to decrease after 2 years, or that it remains a chronic problem after this period of time. The small increase in PN symptoms in those not treated with chemotherapy could be due to older age and an increase in age- and PN-related comorbidity, such as diabetes mellitus, rheumatoid arthritis, and osteoarthritis. Also, we only had data on chemotherapy as primary treatment while it is possible that patients in the “no chemotherapy” group did receive chemotherapy as secondary treatment.

Regarding the association between PN and HRQoL, CRC patients with a high SPN or MPN level reported a worse global quality of life and a worse functioning compared with those with a low level. Previous cross-sectional studies among CRC patients have found similar results. For example, our previous study among CRC survivors 2–11 years after diagnosis showed that those with many neuropathy symptoms reported significant and clinically relevant worse HRQoL scores on all EORTC QLQ-C30 subscales [7]. Another study among oxaliplatin-treated CRC survivors up to 7 years post

† Springer
chemotherapy also found that PN was associated with worse HRQoL [8].

The results of this study regarding both the long-lasting course of SPN and the impact of PN on HRQoL indicate that it is crucial to inform patients and clinicians about CIPN and its impact on patients’ lives. In addition, currently no preventive treatment for CIPN is available. More studies aiming to improve our understanding of the mechanisms underlying the development of CIPN are needed, so targeted interventions can be developed. Several alternative chemotherapy options are available to prevent (severe) CIPN. Evidence shows that shortened durations (3 vs. 6 months) of FOLFOX or CAPOX chemotherapy can be given to stage III colon cancer patients, without compromising survival [24]. CAPOX is preferred, as it results in a lower incidence of long-lasting SPN compared with FOLFOX chemotherapy [25]. For established (painful) CIPN, duloxetine is the only agent recommended in the treatment of CIPN [4]. In addition, preliminary empirical evidence suggests that non-pharmacological treatments such as exercise [26] and cognitive-behavioral therapy [27] may be effective in preventing and/or treating (painful) CIPN. More studies are needed to provide more evidence for the effectiveness of these non-pharmacological treatments. Also, future research should examine possible sociodemographic, clinical, and psychological factors that predict the onset and persistence of CIPN.

The present study has some limitations. First, data on type of chemotherapy, number of chemotherapy cycles, and dose reduction were not available, while these factors are important determinants of CIPN and thereby could have impacted our results [3]. The lack of a clinician-based assessment of CIPN is another limitation, as patient-reported assessments of CIPN should preferably be combined with clinician-rated neurological assessment tools [28]. However, especially patient-reported assessment seems important, as healthcare professionals often underestimate the severity and frequency of neuropathy symptoms [29]. Furthermore, generalization of the results of this study should be done with caution, as eligible patients and the respondents of this study did show some differences in sociodemographic and clinical characteristics. Moreover, as the PROCORE study is still ongoing, not all patients received the questionnaires at 1-year and 2-year follow-up. While no differences in sociodemographic and clinical characteristics were found between patients who completed both baseline and either 1-year or 2-year follow-up and those who completed all three questionnaires, this could have impacted (the strength of) our findings. Finally, it remains unknown whether those lost to follow-up stopped participating due to PN in their hands. If so, this may have resulted in an underestimation of our findings.

Despite these limitations, this is, to the best of our knowledge, the first longitudinal study that examined the association between CIPN and HRQoL among CRC patients up to 2 years after diagnosis. In addition, by examining not only between-patients effects but also within-patient effects in the association between CIPN and HRQoL, a stronger support for causality is provided.

In conclusion, the results of this study indicate that especially SPN symptoms are still prevalent 2 years after diagnosis. In addition, both SPN and MPN were significantly associated with a worse HRQoL. Therefore, it is crucial that patients are informed of both CIPN and the impact on HRQoL. Due to the currently limited treatment options, clinicians may also offer support to CRC survivors by monitoring for the symptoms and supporting survivors in their search for a solution, for example, by informing them about possible benefits of exercise and cognitive-behavioral therapy. Future studies should focus on increasing the understanding of the mechanisms underlying both the development of CIPN and CIPN chronicity, so targeted interventions can be developed to reduce the impact of CIPN on patients’ lives.

Acknowledgments  We would like to thank all patients and their doctors for their (ongoing) participation in PROCORE. Special thanks goes to C. Rolf and F. van Heest, who were willing to function as independent advisors and to answer questions of patients. In addition, we want to thank the following hospitals for their cooperation: Elisabeth-Tw¨eesteden Hospital, Tilburg; Catharina Hospital, Eindhoven; Elkerleik Hospital, Helmond; Máxima Medical Centre, Eindhoven and Veldhoven.

Novelty and impact  Prospective data on the course of chemotherapy-induced peripheral neuropathy (CIPN) and its impact on health-related quality of life (HRQoL) is limited. In this study, especially sensory symptoms were still prevalent 2 years after diagnosis and both sensory and motor symptoms were associated with a worse HRQoL. These findings show the importance of gaining more insight into the mechanisms underlying CIPN, so targeted interventions can be developed to reduce the impact of CIPN on patients’ lives.

Funding information  The present research was supported by the Center of Research on Psychology in Somatic Disorders (CoRPS), Tilburg University, the Netherlands; the Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands; and an Aspasia grant of the Netherlands Organization for Scientific Research (The Hague, The Netherlands).

Data availability  The data that support the findings of this study are available from the profiles registry (www.profilesregistry.nl).

Compliance with ethical standards  Conflict of interest  The authors declare that they have no conflict of interest.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by
References

1. Siegel RL, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–93.

2. Nederlandse Kankerregistratie. Cijfers over Kanker. Available from: http://www.cijfersoverkanker.nl/. Accessed 12 Nov 2019.

3. Seretny M, Currie GL, Sema ES, Ramnarine S, Grant R, Macleod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461–70.

4. Hershman DL, Lachetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavalletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–67.

5. Gutiérrez-Gutiérrez G, et al. Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. Clin Transl Oncol. 2010;12(2):81–91.

6. Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer. 2014;22(8):2261–9.

7. Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV. Chemotherapy-induced neuropathy and its association with quality of life among 211-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol. 2013;31(21):2699–707.

8. Toft Hansen C, Donovan KA, Morgan MA, Shibata D, Yeh Y. Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors. Support Care Cancer. 2013;21(12):3307–13.

9. Hsu H-T, Wu LM, Lin PC, Juan CH, Huang YY, Chou PL, et al. Emotional distress and quality of life during folic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: a cross-sectional study. Medicine. 2020;99(6):e19029.

10. Soveri LM, et al. Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy. Acta Oncol. 2019;58(4):398–406.

11. Oh P-J, Lee JR, Kim SK, Kim JH. Changes in chemotherapy-induced peripheral neuropathy, disturbance in activities of daily living, and depression following chemotherapy in patients with colorectal cancer: a prospective study. Eur J Oncol Nurst. 2020;44:101676.

12. van Erning FN, Janssen-Heijnen MLG, Wegdam JA, Slooter GD, Wijman JH, Vreugdenhil A, et al. The course of neuropathic symptoms in relation to adjuvant chemotherapy among elderly patients with stage III colon cancer: a longitudinal study. Clin Colorectal Cancer. 2017;16(3):195–203.

13. Ventzel L, Jensen AB, Jensen AR, Jensen TS, Finnerup NB. Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel. Pain. 2016;157(3):560–8.

14. van de Poll-Franse LV, et al. The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer. 2011;47(14):2188–94.

15. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum. 2003;49(2):156–63.

16. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer. 2005;41(8):1135–9.

17. Fayers PM, et al. EORTC QLQ-C30 scoring manual. 2001.

18. Mols F, van de Poll-Franse LV, Vreugdenhil G, Beijers AJ, Kiesszer JM, Aaronson NK, et al. Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population. Eur J Cancer. 2016;69:28–38.

19. Yeo F, Ng CC, Loh KWJ, Molassiotis A, Cheng HL, Au JSK, et al. Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy. Support Care Cancer. 2019;27(12):4753–62.

20. Niezgoda HE, Pater JL. A validation study of the domains of the core EORTC quality of life questionnaire. Qual Life Res. 1993;2(5):319–25.

21. Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol. 2011;29(1):89–96.

22. Land SR, Kopec JA, Cecchini RS, Ganz PA, Wicand HS, Colangelo LH, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol. 2007;25(16):2205–11.

23. Pachman DR, Qin R, Seisler DK, Smith EML, Beutler AS, Ta LE, et al. Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance). J Clin Oncol. 2015;33(30):3416–22.

24. Boyne DJ, Cuthbert CA, O’Sullivan DE, Sajobi TT, Hilsden RJ, Friedenreich CM, et al. Association between adjuvant chemotherapy duration and survival among patients with stage II and III colon cancer: a systematic review and meta-analysis. JAMA Netw Open. 2019;2(5):e194154.

25. Yoshino T, Yamanaka T, Oki E, Kotaka M, Manaka D, Eto T, et al. Efficacy and long-term peripheral sensory neuropathy of 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: the ACHIEVE phase 3 randomized clinical trial. JAMA Oncol. 2019;5(11):1574–81.

26. Kanzawa-Lee GA, Larson JL, Resnicow K, Smith EML. Exercise effects on chemotherapy-induced peripheral neuropathy: a comprehensive integrative review. Cancer Nurs. 2020;43:E172–85.

27. Knoerl R, Smith EML, Barton DL, Williams DA, Holden JE, Krauss JC, et al. Self-guided online cognitive behavioral strategies for chemotherapy-induced peripheral neuropathy: a multicenter, pilot, randomized, wait-list controlled trial. J Pain. 2018;19(4):382–94.

28. Park SB, et al. Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst. 2019;24(Suppl 2):S13–25.

29. Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, et al. Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer. 2010;46(3):479–94.